NYU BIOMARKER CLINICAL AND EPIDEMIOLOGIC CENTER FOR CANCER

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 肺癌是美国癌症死亡的主要原因。纽约大学癌症早期检测临床和流行病学中心的总体目标是开发和前瞻性地跟踪具有不同环境癌症风险的前工会成员和活跃工会成员的大型地理分散人群，以识别肿瘤前细胞变化和病变，并检测早期癌症。纽约大学的人群将包括许多有吸烟史和/或工作场所暴露史的人。他们将从建筑工会中抽取，过去在公用事业工人、石棉绝缘体、锅炉制造商、钣金工人、木匠和管道安装工中接触石棉是很常见的。 纽约大学中心将有一个检查站来筛选与德克萨斯州一个核武器设施有关的活跃和前工人。纽约大学临床和流行病学中心将促进招募和抽样大量高风险蓝领工人，并对p53和K-ras基因上的DNA加合物、细胞周期蛋白-细胞周期蛋白依赖性激酶的失调、信号传导和Rb通路的失调以及癌基因和肿瘤抑制基因的其他生物测定进行检测，以在最早和最可治疗的阶段检测肿瘤前状态或癌症。将对某些高风险个体进行荧光支气管镜检查，进行支气管刷检和粘膜活检，以评价细胞周期失调。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Lung cancer is the leading cause of cancer death in the US. The overall goal of the NYU Clinical and Epidemiologic Center for the Early Detection of Cancer is to develop and prospectively follow large, geographically dispersed populations of former and active union members of varying environmental cancer risk, to identify preneoplastic cellular changes and lesions, and to detect early cancers. The NYU population will consist of many individuals with a history of smoking and/or workplace exposures. They will be drawn from the building trade unions, where past exposure to asbestos was common among utility workers, asbestos insulators, boilermakers, sheet-metal workers, carpenters, and pipefitters. The NYU Center will have a subcontract to screen active and former workers associated with a nuclear weapons facility in Texas. The NYU Clinical and Epidemiologic Center will facilitate recruitment and sampling of a large cohort of high-risk, blue- collarn workers and that assays for DNA-adducts on p53 and K-ras genes, deregulation of the cyclin-cyclin dependent kinases, deregulation of signaling and Rb pathways, and other bioassays for oncogenes and tumor suppressor genes will detect preneoplastic conditions or cancer in the earliest and most treatable stages. Fluorescence bronchoscopy will be performed on certain high risk individuals for bronchial brush and mucosal biopsies to evaluate cell-cycle deregulation.